Incyte (INCY) Tops Q1 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Incyte (INCY) Tops Q1 EPS by 4c

Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs

May 4, 2017 7:08 AM EDT

$251 million of 2017 first-quarter net product revenues from Jakafi® (ruxolitinib), representing 37 percent growth over the same period last year Expanded ECHO program for epacadostat to include multiple pivotal trials in patients with melanoma, non-small cell lung, head & neck, bladder, and renal cancers in combination with PD-1 inhibitors Olumiant® (baricitinib) approved by the European Commission for the treatment of moderate to severe active rheumatoid arthritis; Complete Response Letter (CRL) for baricitinib issued by the FDA

Conference Call and Webcast Scheduled Today at 10:00... More